Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Nebulized Ketamine for the Treatment of Major Depressive Disorder in an Inpatient Setting: A Midazolam-controlled Randomized Controlled Trial

NCT06752759 is registered in ClinicalTrials.gov with Theresa Jacob, PhD, MPH as lead sponsor.

NCT NCT06752759
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06752759 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Nebulized Ketamine for the Treatment of Major Depressive Disorder in an Inpatient Setting: A Midazolam-controlled Randomized Controlled Trial
Lead sponsor
Theresa Jacob, PhD, MPH
Phase
Phase 3
Overall status
Recruiting
Start date
October 16, 2024
Completion date
September 30, 2027
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

analgesics, non-narcotic, anesthetics agent, anti-anxiety agents, anti-inflammatory agents, non-steroidal, central nervous system agents, depressive symptom, hypnotics and sedatives, ketamine, midazolam, moderate depression, neurotransmitter agents, peripheral nervous system agents, physiologic effects of drugs, psychotropic drugs, sensory system agents, severe depression, tranquilizing agents